Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025
Insmed (Nasdaq: INSM) has announced it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed (Nasdaq: INSM) has announced it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025. The company will host a conference call for investors at 8:00 a.m. ET on the same day to discuss the results and provide a business update.
Participants can join the call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189. The call will be webcast live on Insmed's website. A replay will be available until February 27, 2025, through both dial-in and webcast options, with the webcast archived for 90 days on the company's website.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was -2.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, February 20, 2025, to discuss financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (
A replay of the conference call will be accessible approximately 1 hour after its completion through February 27, 2025, by dialing (800) 770-2030 (
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-on-thursday-february-20-2025-302371620.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.